Indication: Persistent Posttraumatic Headache (PPTH)

A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double-Blind, Placebo-Controlled, Parallel-Group Study Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH)

Persistent Post Traumatic Headache

Drug Study

Principal Investigator: Brian Plato, DO
Norton Neuroscience Institute

Sponsor: Teva Pharmaceuticals

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.